These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 32236956)

  • 1. The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review.
    Barbier L; Ebbers HC; Declerck P; Simoens S; Vulto AG; Huys I
    Clin Pharmacol Ther; 2020 Oct; 108(4):734-755. PubMed ID: 32236956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Biosimilar Nocebo Effect? A Systematic Review of Double-Blinded Versus Open-Label Studies.
    Odinet JS; Day CE; Cruz JL; Heindel GA
    J Manag Care Spec Pharm; 2018 Oct; 24(10):952-959. PubMed ID: 30247100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug Discontinuation in Studies Including a Switch From an Originator to a Biosimilar Monoclonal Antibody: A Systematic Literature Review.
    Bakalos G; Zintzaras E
    Clin Ther; 2019 Jan; 41(1):155-173.e13. PubMed ID: 30551802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction.
    Ingrasciotta Y; Cutroneo PM; Marcianò I; Giezen T; Atzeni F; Trifirò G
    Drug Saf; 2018 Nov; 41(11):1013-1022. PubMed ID: 29796832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
    Mysler E; Azevedo VF; Danese S; Alvarez D; Iikuni N; Ingram B; Mueller M; Peyrin-Biroulet L
    Drugs; 2021 Nov; 81(16):1859-1879. PubMed ID: 34705255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes.
    Cohen HP; Blauvelt A; Rifkin RM; Danese S; Gokhale SB; Woollett G
    Drugs; 2018 Mar; 78(4):463-478. PubMed ID: 29500555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies.
    Numan S; Faccin F
    Adv Ther; 2018 Sep; 35(9):1295-1332. PubMed ID: 30084060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician.
    Moots R; Azevedo V; Coindreau JL; Dörner T; Mahgoub E; Mysler E; Scheinberg M; Marshall L
    Curr Rheumatol Rep; 2017 Jun; 19(6):37. PubMed ID: 28623625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective.
    Kurki P; Barry S; Bourges I; Tsantili P; Wolff-Holz E
    Drugs; 2021 Nov; 81(16):1881-1896. PubMed ID: 34596876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching to biosimilars in the treatment of rheumatic diseases.
    Yoo DH; Choe JY; Shim SC; Suh CH
    Expert Rev Clin Immunol; 2018 Jul; 14(7):557-571. PubMed ID: 29914272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are we ready to close the discussion on the interchangeability of biosimilars?
    Ebbers HC; Schellekens H
    Drug Discov Today; 2019 Oct; 24(10):1963-1967. PubMed ID: 31254488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis.
    Alten R; Markland C; Boyce M; Kawakami K; Muniz R; Genovese MC
    Int J Rheum Dis; 2020 Nov; 23(11):1514-1525. PubMed ID: 32852139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The Polish Task Force position statement on safety of biologic treatment with monoclonal antibodies and soluble receptors].
    Jahnz-Rozyk K; Wiesik-Szewczyk E;
    Pol Merkur Lekarski; 2014 Jul; 37(217):5-9. PubMed ID: 25154192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of switching between rituximab biosimilars in onco-hematology.
    Urru SAM; Spila Alegiani S; Guella A; Traversa G; Campomori A
    Sci Rep; 2021 Mar; 11(1):5956. PubMed ID: 33727667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review.
    McKinnon RA; Cook M; Liauw W; Marabani M; Marschner IC; Packer NH; Prins JB
    BioDrugs; 2018 Feb; 32(1):27-52. PubMed ID: 29344876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Effectiveness of Anti-Tumor Necrosis Factor-Alpha Biosimilar Agents in the Treatment of Psoriasis.
    Reynolds KA; Pithadia DJ; Lee EB; Liao W; Wu JJ
    Am J Clin Dermatol; 2020 Aug; 21(4):483-491. PubMed ID: 32048187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilars in ulcerative colitis: When and for who?
    Ilias A; Gonczi L; Kurti Z; Lakatos PL
    Best Pract Res Clin Gastroenterol; 2018; 32-33():35-42. PubMed ID: 30060937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilars for inflammatory bowel disease: how can healthcare professionals help address patients' concerns?
    Gecse KB; Cumming F; D'Haens G
    Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):143-155. PubMed ID: 30791783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice.
    Solitano V; D'Amico F; Fiorino G; Peyrin-Biroulet L; Danese S
    Expert Rev Clin Immunol; 2020 Oct; 16(10):1019-1028. PubMed ID: 32954893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety outcomes when switching between biosimilars and reference biologics: A systematic review and meta-analysis.
    Herndon TM; Ausin C; Brahme NN; Schrieber SJ; Luo M; Andrada FC; Kim C; Sun W; Zhou L; Grosser S; Yim S; Ricci MS
    PLoS One; 2023; 18(10):e0292231. PubMed ID: 37788264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.